(0.07%) 5 252.20 points
(0.06%) 39 784 points
(-0.07%) 16 387 points
(1.59%) $82.64
(0.52%) $1.727
(0.98%) $2 234.30
(0.53%) $24.88
(1.36%) $922.05
(0.30%) $0.926
(0.70%) $10.84
(0.03%) $0.792
(0.17%) $92.60
-2.50% KRW 6 250.00
Live Chart Being Loaded With Signals
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions...
Stats | |
---|---|
Today's Volume | 818 262 |
Average Volume | 741 806 |
Market Cap | 392.58B |
EPS | KRW0 ( 2024-02-12 ) |
Next earnings date | ( KRW0 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW18.03 (0.29%) |
Volume Correlation
Pharmicell Co., Ltd. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharmicell Co., Ltd. Correlation - Currency/Commodity
Pharmicell Co., Ltd. Financials
Annual | 2023 |
Revenue: | KRW56.23B |
Gross Profit: | KRW14.96B (26.60 %) |
EPS: | KRW59.63 |
Q4 | 2023 |
Revenue: | KRW13.21B |
Gross Profit: | KRW3.60B (27.21 %) |
EPS: | KRW20.55 |
Q3 | 2023 |
Revenue: | KRW12.17B |
Gross Profit: | KRW3.54B (29.07 %) |
EPS: | KRW17.84 |
Q2 | 2023 |
Revenue: | KRW17.74B |
Gross Profit: | KRW4.32B (24.37 %) |
EPS: | KRW10.00 |
Financial Reports:
No articles found.
Pharmicell Co., Ltd.
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators